The dollars are concentrated in the smallest group

Twelve pharmacy identifiers accounted for $42 million—58.4% of all payments identified—in a new federal review of Medicare providers missing from a payment-blocking list. Those identifiers represented only 4.8% of the 249 identifiers associated with payments in the review, a calculation from the inspector general’s payment table shows.

The finding changes how the report’s $72 million total should be read. The biggest dollar category was not simply a late entry on a federal list. It involved a separate regulatory limit: placing a pharmacy on the Centers for Medicare & Medicaid Services Preclusion List does not, by itself, bar payment for dispensing prescriptions written by eligible prescribers.

What’s the Scoop With Broach compared the September inspector general report with CMS’s July proposal to expand preclusion based on owners’ felony convictions. That proposal addresses an important organizational gap. It does not change the separate pharmacy-dispensing limitation in the preclusion provisions reviewed here. Treating the proposal as a complete answer to the audit would obscure where most identified dollars went.

Three payment categories require different fixes

The inspector general examined 1,017 revoked National Provider Identifiers associated with excluded providers or individuals convicted of certain felonies who were absent from the Preclusion List at the end of 2023. The review tracked payments during 2022–2024. It identified $72,004,603 associated with 249 identifiers; the other 768 had no identified Part C service or Part D prescription payments.

Timing problems and errors accounted for $24,335,172, or 33.8% of the total, combining Part C services and drugs prescribed under Part D. A separate category covered $5,648,262 paid for Part C services to 33 organizational identifiers whose owners were excluded or had felony convictions—7.8% of the total. Pharmacy dispensing accounted for the remaining $42,021,169.

These are identifiers, not necessarily unique businesses or people. Thirty-six identifiers appeared in both the Part C and prescribing columns, and another four appeared in the Part C and pharmacy columns. The newsroom used OIG’s unduplicated total of 249 for the pharmacy share, rather than adding the table’s overlapping column counts. The source also flags minor rounding differences in its dollar totals.

An ownership proposal leaves a distinct dispensing question

CMS’s July 6 proposed rule would expand the felony-conviction ground for preclusion to include a provider or prescriber’s owner, managing employee, managing organization, corporate director or officer. CMS explained that these parties can influence operations and that the change would align preclusion more closely with other Medicare enrollment controls.

That is a concrete response to the type of organizational separation described by OIG. The agency currently treats different taxpayer identification numbers as separate entities for preclusion, with additional complications when one taxpayer number has multiple provider identifiers. OIG also found that rendering-provider information is not mandatory in encounter data submitted to Part C plans, limiting a separate way to identify the responsible individual.

The final-rule package remained listed as pending at the Office of Information and Regulatory Affairs when checked October 6; it had arrived September 21. The published provision is therefore a proposal in this comparison. CMS did not estimate savings for the ownership expansion, saying it could not predict how often the new authority would be used. The audit’s $5.6 million category cannot be treated as a guaranteed recovery or a forecast of future savings.

Preclusion is only one safeguard

OIG’s report does not establish that all $72 million was fraud or all payments violated the same rule. Separate prohibitions on contracting with or paying excluded providers still apply, regardless of whether CMS lists them. For pharmacies, the absence of an automatic preclusion-based dispensing block does not erase those exclusion obligations.

CMS also reported corrective work: it precluded 537 of the 1,017 reviewed identifiers and planned to preclude 76 more. It said preclusion was inapplicable to 232 and that it could not preclude 172 organizational identifiers. Those actions demonstrate progress, but they do not supply a current payment total or demonstrate that the pharmacy limitation has been resolved. OIG issued no formal recommendations in this data brief; the records identify distinct controls that need separate evaluation.

Sources and further reading

OIG A-02-24-01013, issued September 28 2026 ↗

Official Federal Register PDF, July 6 2026, pages 41295–41296 preclusion change and impact discussion ↗

Proposed-rule HTML, Section V.B.3 and regulatory impact section ↗

OIRA pending final-rule review, received September 21, checked October 6 ↗

CMS current preclusion explanation ↗

Photograph rights and reuse ↗